SCHEMBL5637366

SCHEMBL5637366

CC(C)(C)OC(=O)C1CNCCN1c1ccc2ccccc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.46
CYP3A4 P08684 2/20 0.46
HSD17B10 Q99714 2/20 0.46
ALDH1A1 P00352 2/20 0.45
HTR3E A5X5Y0 1/20 0.45
USP2 O75604 1/20 0.45
HTR3B O95264 1/20 0.45
CYP1A2 P05177 1/20 0.45
ADRB1 P08588 1/20 0.45
HTR1A P08908 1/20 0.45
HTR2C P28335 1/20 0.45
MAPK1 P28482 1/20 0.45
SLC6A4 P31645 1/20 0.45
HTR7 P34969 1/20 0.45
HTT P42858 1/20 0.45
HTR3A P46098 1/20 0.45
HTR6 P50406 1/20 0.45
PMP22 Q01453 1/20 0.45
HTR3D Q70Z44 1/20 0.45
HTR3C Q8WXA8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11081509 0.81 KDM4E (0.48) KDM4ECYP3A4HSD17B10ALDH1A1HTR3E
SCHEMBL27561229 0.79 SLC6A2 (0.44) HSD17B10ALDH1A1HTR3EUSP2HTR3B
SCHEMBL6992310 0.77 HTR2C (0.39) HTR2CMAPK1
SCHEMBL15415761 0.77 GPR119 (0.34) MAPK1
SCHEMBL6069451 0.76 FPR2 (0.37) HTR2CACACBACACA
SCHEMBL6069866 0.76 FPR2 (0.39) HTR2CACACBACACA
SCHEMBL4573662 0.75 KDM4E (0.55) KDM4ECYP3A4HSD17B10ALDH1A1HTR3E
SCHEMBL4133764 0.75 HTR2C (0.36) HTR2CMAPK1HTR6
SCHEMBL16087143 0.75 KDM4E (0.57) KDM4ECYP3A4HSD17B10ALDH1A1HTR3E
SCHEMBL6766547 0.75 HTR2C (0.57) KDM4ECYP3A4HSD17B10ALDH1A1HTR3E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220856-B2 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2007-05-22 US disclosed
EP-1534681-A1 SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS SCHERING AKTIENGESELLSCHAFT (DE) 2005-06-01 EP disclosed
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2004-04-15 US disclosed
WO-2004002960-A1 SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS SCHERING AKTIENGESELLSCHAFT (DE) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists CCR5, CXCR3, CCR2 KDM4E 3993/4885CYP3A4 662/4885HSD17B10 2209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.